Want to contact a District of Columbia Aczone attorney? ...Get a free case evaluation from one of our District of Columbia Aczone attorneys now.
Home : FDA Drug Database : Aczone : News Articles
Aczone - News Articles
-
May 9, 2008
RedOrbit, TX -
Scratching of the skin contaminated with nasal secretions may implant the spores and cause secondary lesions.6 Dapsone is the recommended antimicrobial ... -
Jul 26, 2007
PR Newswire (press release), NY -
from R&D expense in the second quarter last year primarily due to decreased spending on Aczone(TM), lemuteporfin and Atrigel(R) projects. ... -
Jul 23, 2007
MSN Money -
QLT announces FDA filing and review of Aczone labeling supplement for removal of blood screening requirement Co announces that the FDA has accepted for filing and review the co's labeling supplement for Aczone to request the removal of the glucose-6-phosphate dehydrogenase screening and ... -
Jul 26, 2007
Globe and Mail, Canada -
refinancing of convertible notes, a sale or lease of its real estate, partnering its acne drug Aczone, and bank financing, according to Mr. Gowd. Westwind Partners analyst Aaron Bennett weighs in by suggesting investors will likely be disappointed in the timing and/or valuation of ... -
Jul 26, 2007
Canada East, Canada -
VANCOUVER (CP) - QLT Inc. (TSX:QLT) took a US$109.9-million charge in the second quarter after losing a lawsuit related to its Visudyne eye drug, the company said Thursday as it reported its financial results."We are continuing to seek legal advice regarding our next ...
-
Jul 26, 2007
The Chronicle Journal, Canada -
By The Canadian Press VANCOUVER (CP) - QLT Inc. (TSX:QLT) suffered a second-quarter net loss of US$68.7 million as the drug developer booked a ... -
Jul 26, 2007
Reuters -
Robert L. Butchofsky was appointed as President and Chief Executive Officer and a Director of QLT in February 2006 following his earlier appointment. .. Full Bio Full Management Team Insider Trading ... -
Jul 22, 2007
Trading Markets, CA -
TO) on Monday revealed that the FDA accepted for filing and review, QLT USA, Inc.'s labeling supplement, for Aczone to request the removal of the glucose-6-phosphate dehydrogenase screening and blood monitoring requirements from its current label. The company noted that a decision by the ... -
Jul 23, 2007
StreetInsider.com (subscription), MI -
QLT Inc. (NASDAQ: QLTI) said the FDA has accepted for filing and review QLT USA, Inc.'s labeling supplement for Aczone to request the removal of the glucose-6-phosphate dehydrogenase screening and blood monitoring requirements from its current label. A decision by the FDA on the label ... -
Jul 23, 2007
Compliance Home, IA -
Aczone has the potential to be a key contributor to our growth if this label revision is ultimately approved by the FDA," said Bob Butchofsky, President and Chief Executive Officer of QLT.The sNDA submitted at the end of May 2007 is primarily based on the Phase ...
Want to contact a District of Columbia Aczone attorney? ...Get a free case evaluation from one of our District of Columbia Aczone attorneys now.
